Ainos Stock
Ainos, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Chun-Hsien Tsai
- Employees
- 41
- Market cap
- $7 M
- IPO
- 08/01/2021
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as…
Ainos stock: price history
1D
-3.8%
1W
-23.7%
1M
-33.1%
6M
-53.1%
YTD
-43.7%
1Y
-77.1%
2Y
-64.9%
5Y
-99.7%
10Y
–
Next earnings date
Next earnings date
No date known
Volatility around earnings
~12% weaker price swings than usual
Ask the agents about Ainos
Ainos stock metrics
P/E
-0.37
P/B
2.07
EV/EBITDA
-2.14
RETURN ON EQUITY
-139.9%
NET MARGIN
-3,022,849.3%
DEBT/EQUITY
4.21
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
46.7%
FLOAT SHARES
3,447,070
AVG. DAILY VOLUME (30D)
249,377
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Ainos stock
What does Ainos do?
Ainos, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Chun-Hsien Tsai, the company employs around 41 people.
The IPO was on 08/01/2021; the stock trades on NASDAQ under the ticker AIMD.
When does Ainos report next?
Around past earnings, price swings were roughly -12% stronger than usual.
Does Ainos pay a dividend?
No, Ainos currently does not pay a dividend.
Which stocks are comparable to Ainos?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Ainos stock analyzed?
Clicking "Analyze stock" lets five strategies assess Ainos against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.